359 related articles for article (PubMed ID: 28839442)
1. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.
Tornai T; Palyu E; Vitalis Z; Tornai I; Tornai D; Antal-Szalmas P; Norman GL; Shums Z; Veres G; Dezsofi A; Par G; Par A; Orosz P; Szalay F; Lakatos PL; Papp M
World J Gastroenterol; 2017 Aug; 23(29):5412-5421. PubMed ID: 28839442
[TBL] [Abstract][Full Text] [Related]
2. Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis.
Dhillon AK; Kummen M; Trøseid M; Åkra S; Liaskou E; Moum B; Vesterhus M; Karlsen TH; Seljeflot I; Hov JR
Liver Int; 2019 Feb; 39(2):371-381. PubMed ID: 30269440
[TBL] [Abstract][Full Text] [Related]
3. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
[TBL] [Abstract][Full Text] [Related]
4. Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis.
Nielsen MJ; Thorburn D; Leeming DJ; Hov JR; Nygård S; Moum B; Saffioti F; Gilja OH; Boberg KM; Mazza G; Røsjø H; Pinzani M; Karlsen TH; Karsdal MA; Vesterhus M
Aliment Pharmacol Ther; 2018 Jul; 48(2):179-189. PubMed ID: 29851098
[TBL] [Abstract][Full Text] [Related]
5. The impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis.
Navaneethan U; Venkatesh PG; Lashner BA; Shen B; Kiran RP
Aliment Pharmacol Ther; 2012 May; 35(9):1045-53. PubMed ID: 22428605
[TBL] [Abstract][Full Text] [Related]
6. Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.
Bossen L; Vesterhus M; Hov JR; Färkkilä M; Rosenberg WM; Møller HJ; Boberg KM; Karlsen TH; Grønbæk H
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00315. PubMed ID: 33646203
[TBL] [Abstract][Full Text] [Related]
7. Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.
Kovacs G; Sipeki N; Suga B; Tornai T; Fechner K; Norman GL; Shums Z; Antal-Szalmas P; Papp M
PLoS One; 2018; 13(3):e0194166. PubMed ID: 29590158
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis.
Papp M; Sipeki N; Vitalis Z; Tornai T; Altorjay I; Tornai I; Udvardy M; Fechner K; Jacobsen S; Teegen B; Sumegi A; Veres G; Lakatos PL; Kappelmayer J; Antal-Szalmas P
J Hepatol; 2013 Sep; 59(3):457-66. PubMed ID: 23639483
[TBL] [Abstract][Full Text] [Related]
9. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.
de Vries EMG; Färkkilä M; Milkiewicz P; Hov JR; Eksteen B; Thorburn D; Chazouillères O; Pares A; Nygård S; Gilja OH; Wunsch E; Invernizzi P; Carbone M; Bernuzzi F; Boberg KM; Røsjø H; Rosenberg W; Beuers UH; Ponsioen CY; Karlsen TH; Vesterhus M
Liver Int; 2017 Oct; 37(10):1554-1561. PubMed ID: 28267887
[TBL] [Abstract][Full Text] [Related]
10. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.
Tornai T; Tornai D; Sipeki N; Tornai I; Alsulaimani R; Fechner K; Roggenbuck D; Norman GL; Veres G; Par G; Par A; Szalay F; Lakatos PL; Antal-Szalmas P; Papp M
Sci Rep; 2018 Jan; 8(1):399. PubMed ID: 29321484
[TBL] [Abstract][Full Text] [Related]
11. Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD.
Fevery J; Van Steenbergen W; Van Pelt J; Laleman W; Hoffman I; Geboes K; Vermeire S; Nevens F
Aliment Pharmacol Ther; 2016 Mar; 43(5):612-20. PubMed ID: 26748470
[TBL] [Abstract][Full Text] [Related]
12. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass.
Bansi DS; Fleming KA; Chapman RW
Gut; 1996 Mar; 38(3):384-9. PubMed ID: 8675091
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
[TBL] [Abstract][Full Text] [Related]
14. The Natural History of Primary Sclerosing Cholangitis in Children: A Large Single-Center Longitudinal Cohort Study.
Valentino PL; Wiggins S; Harney S; Raza R; Lee CK; Jonas MM
J Pediatr Gastroenterol Nutr; 2016 Dec; 63(6):603-609. PubMed ID: 27504812
[TBL] [Abstract][Full Text] [Related]
15. Association between serum IgG level and clinical course in primary sclerosing cholangitis.
Hippchen T; Sauer P; Göppert B; Schirmacher P; Gotthardt DN; Weiss KH; Stremmel W; Rupp C
BMC Gastroenterol; 2019 Aug; 19(1):153. PubMed ID: 31455255
[TBL] [Abstract][Full Text] [Related]
16. Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype.
Sowa M; Kolenda R; Baumgart DC; Pratschke J; Papp M; Tornai T; Suchanski J; Bogdanos DP; Mytilinaiou MG; Hammermann J; Laass MW; Conrad K; Schramm C; Franke A; Roggenbuck D; Schierack P
Front Immunol; 2018; 9():1959. PubMed ID: 30233574
[No Abstract] [Full Text] [Related]
17. Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis.
Chung BK; Guevel BT; Reynolds GM; Gupta Udatha DB; Henriksen EK; Stamataki Z; Hirschfield GM; Karlsen TH; Liaskou E
J Autoimmun; 2017 Feb; 77():45-54. PubMed ID: 27784538
[TBL] [Abstract][Full Text] [Related]
18. IgA anti-actin antibodies in children with celiac disease: comparison of immunofluorescence with Elisa assay in predicting severe intestinal damage.
Bazzigaluppi E; Parma B; Tronconi GM; Corsin P; Albarello L; Mora S; Barera G
Ital J Pediatr; 2010 Mar; 36():25. PubMed ID: 20298549
[TBL] [Abstract][Full Text] [Related]
19. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner.
Trivedi PJ; Tickle J; Vesterhus MN; Eddowes PJ; Bruns T; Vainio J; Parker R; Smith D; Liaskou E; Thorbjørnsen LW; Hirschfield GM; Auvinen K; Hubscher SG; Salmi M; Adams DH; Weston CJ
Gut; 2018 Jun; 67(6):1135-1145. PubMed ID: 28428344
[TBL] [Abstract][Full Text] [Related]
20. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.
Fraga M; Fournier N; Safroneeva E; Pittet V; Godat S; Straumann A; Nydegger A; Vavricka SR; Moradpour D; Schoepfer AM;
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):91-97. PubMed ID: 27622999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
